
BNTC Stock Forecast & Price Target
BNTC Analyst Ratings
Bulls say
Benitec Biopharma Inc is positioned favorably due to its promising clinical results from the BB-301 therapeutic development for Oculopharyngeal Muscular Dystrophy (OPMD), demonstrating a significant rate of patient improvement in critical swallowing capabilities. The company's potential for productive regulatory interactions may accelerate its path to market, possibly through conditional or expedited approval avenues, enhancing the likelihood of commercial success. Additionally, the sustained improvements observed in patients indicate a high degree of efficacy and an opportunity for premium pricing based on the inherent value of the BB-301 therapy, positively impacting long-term growth prospects.
Bears say
Benitec Biopharma Inc reported a first-quarter loss of $0.21 per share, which was better than an anticipated loss of $0.41 per share, primarily attributed to an increased number of shares outstanding. The company's prospects are hindered by several key risks, including potential delays or failures in securing regulatory approval for its lead therapeutic candidate, BB-301, as well as concerns related to negative data from ongoing clinical trials and slower market adoption. Additionally, long-term financial health is jeopardized due to risks of shareholder dilution resulting from recent transactions, contributing to an overall negative outlook for the company's stock.
This aggregate rating is based on analysts' research of Benitec Biopharma Limited Sponsored ADR and is not a guaranteed prediction by Public.com or investment advice.
BNTC Analyst Forecast & Price Prediction
Start investing in BNTC
Order type
Buy in
Order amount
Est. shares
0 shares